Pss5 - Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Intravitreal Aflibercept: The Aqua Study

Abstract

OBJECTIVES:The systematic synthesis of drug's safety data constitutes a valuable tool in clinical and/or regulatory decisions. This systematic review aims to characterize and review the methodology of the systematic reviews reporting ophthalmic adverse drug reactions. METHODS: This systematic review followed the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-analyses guide. MEDLINE and EMBASE databases were searched, by all Ophthalmology journals. All systematic reviews reporting ophthalmic adverse drug reactions in the last decade were included. Data on methodology were extracted. Methodological quality was assessed through AMSTAR 2 scale. Descriptive analysis was performed. RESULTS: Twenty-one systematic reviews were identified. Almost 60% of the systematic reviews reported non-ophthalmic drugs. Nine (43%) systematic reviews did not follow any recommendation. A search filter was not applied in 48% systematic reviews. Observational data was the source of information most included. The methodological quality was assessed in 57% systematic reviews. A meta-analysis was performed in 57% systematic reviews. The protocol's elaboration, the explanation of the sources of information and the list of excluded articles were the domains less performed in the systematic reviews. CONCLUSIONS: The systematic reviews reporting ophthalmic adverse drug reactions diverged in some methodological aspects. Such issue deserves further investigation since that discrepancies may lead to biased conclusions and, consequently, impact clinical and/or regulatory decisions.

Daily Functionality of People with Low Vision: The Impact of Visual Acuity, Depression, and Life Orientation—A Cross-Sectional Study

“…On the other hand, "visual functioning" is commonly assessed using several questionnaires such as Visual Function-14 (VF-14) [31] and the new Life for Low Vision Questionnaire (LIFE4LVQ) [32], which measure the impact of LV on activities of daily living (ADL). These questionnaires specifically measure limitations in daily activities (disability and/or dependence) associated with vision-dependent tasks such as reading, driving, and shopping, and they have been used to evaluate outcomes of rehabilitation services or even clinical trials [33][34][35][36].…”

Predictors of vision‐related quality of life in patients with macular oedema receiving intra‐vitreal anti‐VEGF treatment

“…However, although the association between visual acuity and (Vr)QoL is generally accepted in medical practice, little is known about other clinical and demographic factors that may be predictive of (Vr)QoL. This is also the case for patients with macular oedema who receive intravitreal anti‐vascular endothelial growth factor (anti‐VEGF), a treatment that reduces the progression of visual loss 15–20 . Due to the long treatment duration, as well as the high frequency and the invasive nature of the injections, patients often experience a relatively high treatment burden 21 …”

“…This is also the case for patients with macular oedema who receive intravitreal anti-vascular endothelial growth factor (anti-VEGF), a treatment that reduces the progression of visual loss. [15][16][17][18][19][20] Due to the long treatment duration, as well as the high frequency and the invasive nature of the injections, patients often experience a relatively high treatment burden. 21 Patient Reported Outcome Measures (PROMs) are increasingly used to evaluate the burden of disease, to improve shared-decision making and support patients in discussing their concerns.…”